Authors
Harin Padma-Nathan, Wayne JG Hellstrom, Fran E Kaiser, Richard F Labasky, Tom F Lue, Wolfram E Nolten, Paul C Norwood, Craig A Peterson, Ridwan Shabsigh, Peter Y Tam, Virgil A Place, Neil Gesundheit, Christy Cowley, Kerry J Nemo, Alfred P Spivack, Darby E Stephens, Leslie K Todd
Publication date
1997/1/2
Journal
New England Journal of Medicine
Volume
336
Issue
1
Pages
1-7
Publisher
Massachusetts Medical Society
Description
Background
Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat this disorder.
Methods
Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. The men were first tested in the clinic with up to four doses of the drug (125, 250, 500, and 1000 μg); those who had sufficient responses were randomly assigned to treatment with either the effective dose of alprostadil or placebo for three months at home.
Results
During in-clinic testing, 996 men (65.9 percent) had erections sufficient for intercourse. Of these men, 961 reported the results of at least one home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully at least once, as compared with 93 of the 500 who …
Total citations
Scholar articles
H Padma-Nathan, WJG Hellstrom, FE Kaiser… - New England Journal of Medicine, 1997